Upstream Bio (NASDAQ:UPB) Stock Price Up 4.8% – Should You Buy?

Upstream Bio, Inc. (NASDAQ:UPB) rose 4.8% on Wednesday . The company traded as high as $30.36 and last traded at $30.6070. Approximately 47,436 shares traded hands during trading, a decline of 88% from the average daily volume of 402,277 shares. The stock had previously closed at $29.21.

Analyst Upgrades and Downgrades

UPB has been the topic of a number of research analyst reports. Truist Financial initiated coverage on shares of Upstream Bio in a research report on Tuesday, October 14th. They set a “buy” rating and a $47.00 price target on the stock. Evercore ISI initiated coverage on Upstream Bio in a research note on Tuesday, November 18th. They issued an “outperform” rating and a $40.00 price objective on the stock. Mizuho raised Upstream Bio to a “strong-buy” rating in a research note on Thursday, December 18th. Lifesci Capital assumed coverage on Upstream Bio in a report on Tuesday, December 2nd. They issued an “outperform” rating and a $43.00 target price for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Upstream Bio in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $45.25.

Upstream Bio Stock Up 4.3%

The company has a 50-day moving average of $25.72 and a 200-day moving average of $18.86. The company has a market cap of $1.65 billion, a PE ratio of -16.27 and a beta of 1.83.

Upstream Bio (NASDAQ:UPB) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($0.78) by $0.15. The business had revenue of $0.68 million for the quarter, compared to analysts’ expectations of $0.65 million. Upstream Bio had a negative return on equity of 28.71% and a negative net margin of 4,366.77%. As a group, equities analysts predict that Upstream Bio, Inc. will post -4.3 EPS for the current year.

Hedge Funds Weigh In On Upstream Bio

Hedge funds have recently modified their holdings of the company. Woodline Partners LP grew its holdings in shares of Upstream Bio by 7.9% in the third quarter. Woodline Partners LP now owns 602,252 shares of the company’s stock valued at $11,328,000 after acquiring an additional 44,000 shares in the last quarter. Verition Fund Management LLC boosted its position in Upstream Bio by 40.3% in the third quarter. Verition Fund Management LLC now owns 47,001 shares of the company’s stock worth $884,000 after purchasing an additional 13,496 shares during the last quarter. Prelude Capital Management LLC bought a new position in Upstream Bio in the 3rd quarter valued at $296,000. Parkman Healthcare Partners LLC increased its position in shares of Upstream Bio by 17.9% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 843,502 shares of the company’s stock valued at $15,866,000 after purchasing an additional 127,998 shares during the last quarter. Finally, Millennium Management LLC bought a new stake in shares of Upstream Bio during the 3rd quarter worth $755,000.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.